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Abstract
Background: The BH3-only protein Bid is an important component of death receptor-mediated caspase activation. Bid is
cleaved by caspase-8 or -10 into t-Bid, which translocates to mitochondria and triggers the release of caspase-activating
factors. Bid has also been reported to be cleaved by other proteases.
Methodology/Principal Findings: To test the hypothesis that Bid is a central mediator of stress-induced apoptosis, we
investigated the effects of a small molecule Bid inhibitor on stress-induced apoptosis, and generated HeLa cells deficient for
Bid. Stable knockdown of bid lead to a pronounced resistance to Fas/CD95- and TRAIL-induced caspase activation and
apoptosis, and significantly increased clonogenic survival. While Bid-deficient cells were equally sensitive to ER stress-
induced apoptosis, they showed moderate, but significantly reduced levels of apoptosis, as well as increased clonogenic
survival in response to the genotoxic drugs Etoposide, Oxaliplatin, and Doxorubicin. Similar effects were observed using the
Bid inhibitor BI6C9. Interestingly, Bid-deficient cells were dramatically protected from apoptosis when subtoxic
concentrations of ER stressors, Etoposide or Oxaliplatin were combined with subtoxic TRAIL concentrations.
Conclusions/Significance: Our data demonstrate that Bid is central for death receptor-induced cell death and participates
in anti-cancer drug-induced apoptosis in human cervical cancer HeLa cells. They also show that the synergistic effects of
TRAIL in combination with either ER stressors or genotoxic anti-cancer drugs are nearly exclusively mediated via an
increased activation of Bid-induced apoptosis signalling.
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Introduction
The members of the Bcl-2 family of proteins are key players in
cellular life and death decisions during apoptosis [1]. The two pro-
apoptotic, multi-domain Bcl-2 family proteins Bax and Bak control
mitochondrial outer membrane permeabilization (MOMP) during
apoptosis, an important process leading to the activation of
caspase-dependent and caspase-independent cell death pathways
[2]. Indeed, Bax and Bak have been considered to represent the
‘gateway’ of apoptosis, as cells from Bax/Bak double knock-out
animals are resistant to most apoptosis-inducing stimuli [3,4]. The
activation of Bax and Bak involves conformational changes,
membrane insertion, and oligomerisation, with their pro-apoptotic
activity inhibited by anti-apoptotic, multidomain Bcl-2 family
proteins such as Bcl-2 and Bcl-xL.
Bid is a member of the Bcl-2-homology domain (BH)-3-only
family of pro-apoptotic proteins that initiate apoptotic cell death
[5]. Similar to the BH3-only proteins Puma and Bim, it is able to
neutralize the anti-apoptotic activity of most anti-apoptotic Bcl-2
family members, including Bcl-2, Bcl-xL, Mcl-1, and Bcl-w [6–8].
There is also strong evidence supporting the hypothesis that Bid is
able to directly activate Bax and Bak to trigger the release of
caspase-activating factors from mitochondria [9–11]. Bid is also
involved in mitochondrial remodelling during apoptosis and
maybe required for the complete release of caspase-activating
factors from mitochondria [12]. bid is a p53 target gene [13].
However, Bid is constitutively expressed in many transformed and
non-transformed cells, and its main mechanism of activation
involves a series of posttranslational modifications including
proteolytic cleavage, myristoylation, phosphorylation, and trans-
location to mitochondria [14–17]. During death receptor-induced
apoptosis, Bid is activated through cleavage by caspase-8 or
caspase-10, generating a truncated form, t-Bid, [18,19]. Bid has
also been reported to be proteolytically activated by other
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during apoptosome-dependent apoptosis [20], and caspase-2,
linking Bid to other stress-induced apoptosis pathways [21,22].
Bid has also been suggested to be cleaved by granzymes, calpains,
and cathepsins in the loop connecting alpha helices 2 and 3,
generating cleavage products that may also induce the release of
caspase-activating factors from mitochondria [23–29]. Finally, full-
length Bid may also have the capacity to translocate to
mitochondria and activate apoptosis without previous cleavage
by caspase-8 or other proteases [30–32]. Taken together these
data suggest that Bid may be a central sensor linking stress
signaling and (patho)physiological protease activation to the
activation of the mitochondrial apoptosis pathway.
Interestingly, bid-deficient mice presented with a relatively mild
phenotype, but showed a prominent resistance to Fas-dependent
apoptosis of hepatocytes [33]. Recently, Bid has also been
suggested to play a role in anti cancer drug- and endoplasmic
reticulum (ER) stress-induced apoptosis in human cells [34–36],
although recent studies in bid-deficient murine cells could not
identify such a role for Bid [37]. The present study was therefore
undertaken to comprehensively explore the role of Bid in death
receptor-, genotoxic drug-, and ER stress-induced apoptosis in
human cervical cancer HeLa cells.
Results
Generation of bid-deficient HeLa Cells
In order to study the role of Bid in death receptor- and drug-
induced apoptosis, gene silencing using three different shRNA
constructs targeting different regions of bid was performed as
described in Materials and Methods. Western blot analysis of
established stable cell lines demonstrated different levels of
reduction in Bid protein expression compared to cells transfected
with a scrambled control sequence (Fig. 1 A). These reduced Bid
levels correlated with reduced executioner caspase activity in
response to an activating Fas antibody (clone CH11), as
determined by analyzing the cleavage of the fluorogenic caspase
substrate Ac-DEVD-AMC (Fig. 1 B). The Bid knockdown clone 1
(hereafter designated as HeLa Bid kd) was further analyzed as this
clone demonstrated maximal knockdown of Bid expression,
whereas the expression of other BH3-only proteins, Bcl-2 family
members, or other key proteins involved in caspase activation were
not altered (Fig. 1 C). Furthermore, re-introduction of ectopically
expressed bid (Fig. 1 D) was able to re-sensitize this clone to Fas-
induced caspase activation and apoptosis (Fig. 1 E), indicating that
the reduction in caspase activity after death receptor activation
was due to the lack of Bid expression.
Bid is required for Fas/CD95- and TRAIL-induced cell
death of HeLa Cells
We next compared the effect of the bid knockdown to death
receptor-induced apoptosis triggered by the activating Fas
antibody or by treatment with recombinant human TRAIL
(TR). Dose-response analyses demonstrated that the knockdown of
bid potently reduced DEVD cleavage activity in response to both
stimuli compared to a control clone transfected with a scrambled
sequence (Fig. 2 A, B). Procaspase-3 processing, poly-ADP-ribose
polimerase (PARP) cleavage and phosphatidylserine exposure
were analyzed by Western blotting and flow cytometry (Fig. 2 C,
D, E, F). The kinetics of procaspase-3 processing corresponded
with the generation of the caspase-cleaved 85 kDa PARP-
fragment, the latter being detectable 2 h after TRAIL/cyclohex-
imide (Chx) and 4 h after Fas/Chx incubation. In HeLa Bid kd
cells, procaspase-3 processing, cleaved PARP levels, and the
accumulation of Annexin V-positive cells were significantly
reduced. Importantly, the knockdown of bid also significantly
increased the clonogenic survival of HeLa cells in response to
TRAIL and Fas activation as analyzed in colony formation assays
(Fig. 3 A, B, C, D).
In contrast to death receptor-induced apoptosis, HeLa Bid kd
cells were not protected from caspase activation and cell death
after exposure to the protein kinase inhibitor Staurosporine (STS),
demonstrating that these cells did not acquire a general resistance
against apoptosis activation (Fig. 4 A, B).
To confirm the results of the bid knockdown in a different
approach, HeLa cells were treated with the synthetic Bid inhibitor
BI6C9 [38]. Cells treated with BI6C9 were significantly protected
against death receptor-induced apoptosis (Fig. 4 C), while the
inhibitor had no significant effect on cell death induced by STS
(Fig. 4 D).
ER stress-induced apoptosis by Tunicamycin does not
require Bid
It has been previously suggested that ER stress can trigger
caspase-8 activation and downstream induction of the intrinsic
apoptosis pathway via Bid processing [34,39]. To test this
hypothesis in the HeLa Bid kd cells, ER stress was induced using
Tunicamycin (Tu), Thapsigargin (Th) and Brefeldin A. The
antibiotic Tunicamycin inhibits N-linked glycosylation of nascent
proteins, leading to an accumulation of hypoglycosylated proteins
in the ER lumen, resulting in the activation of ER stress responses
and, if persisting, to ER stress-induced apoptosis. Treatment of
HeLa Bid kd cells and control HeLa cells with Tunicamycin
resulted in a similar induction in protein levels of the ER resident
molecular chaperones Grp78 and Grp94, which are known ER
stress response target genes (Fig. 5 A), but also resulted in similar
levels of caspase activation (Fig. 5 B, E), apoptosis and cell death
(Fig. 5 F). These results suggested that Bid did not affect the
unfolded protein response (UPR) and was not required for ER
stress-induced apoptosis. Similar results were obtained when ER
stress was induced by Brefeldin A or Thapsigargin, which inhibit
ER to Golgi transport and the sarco/endoplasmic reticulum Ca
2+
ATPases, respectively (Fig. 5 C, D).
The knockdown of bid abolishes the synergistic effect of
Tunicamycin and TRAIL on apoptosis in HeLa cells
ER stress induced by Brefeldin A has been shown previously to
synergize with an agonistic Fas antibody [40], and Tunicamycin
has been shown to synergize with TRAIL-induced apoptosis by
increasing the expression of the TRAIL receptor death receptor 5
(DR5) [41]. Although our results indicate that Bid is not directly
involved in ER stress-mediated apoptosis, it may play an
important role in the synergistic effects of ER stress-inducing
agents and death receptor ligands. Treatment of HeLa control
cells or Bid kd cells with Tunicamycin potently up regulated DR5,
both at the mRNA (data not shown) and the protein level, while
death receptor 4 (DR4) levels were not affected (Fig. 6 A). Pre-
treatment with low doses of the ER stressors Tunicamycin and
Thapsigargin followed by exposure to low doses of TRAIL
induced a dramatic increase in caspase activity to levels higher
than predicted from the individual treatments (Fig. 6 B, C). These
synergistic effects were confirmed by Western blotting which
detected increased procaspase-3 processing, cleavage of PARP,
and cleavage of Bid (Fig. 6 D). In addition, flow cytometry analysis
of Annexin-V binding indicated enhanced phosphatidylserine
exposure after combined treatment with TRAIL and Tunicamycin
(Fig. 6 E). The knockdown of bid completely abolished these
Bid in Apoptosis
PLoS ONE | www.plosone.org 2 July 2008 | Volume 3 | Issue 7 | e2844Figure 1. Generation of stable Bid deficient HeLa cells. A) Cells were stably transfected with plasmids encoding one of three different bid-
specific shRNAs or a scrambled control shRNA as described in Materials and Methods. For analysis of the bid knockdown, cells were subjected to
Western blotting with a polyclonal Bid antibody. a-Tubulin served as a loading control. B) Control cells expressing the scrambled (Ctrl 1, Ctrl 2), or the
bid specific shRNA (Bid kd 4) and clone (Bid kd 1) were incubated with Cycloheximide (CHX) (1 mg/ml) and an agonistic Fas antibody or vehicle (clone
CH11) at the indicated concentrations or vehicle for 4 h. Caspase-3 like activity was measured by cleavage of the fluorigenic substrate Ac-DEVD-AMC.
Data are means+/2SD from n=3 separate experiments. # p,0.05: difference from control cells (Ctrl). C) Cell lysates were subjected to Western
blotting with antibodies for the indicated proteins, as described in Materials and Methods. D) HeLa Bid kd cells were stably transfected with a vector
coding for YFP-bid-CFP (GFP-Bid); cell lysates were subjected to Western blotting with GFP and Bid antibodies. E) HeLa Bid kd cells expressing GFP-Bid
were treated with CHX (1 mg/ml) and an activating Fas antibody (100 ng/ml). Controls were treated with vehicle for 4 h; caspase-3 like activity was
measured by cleavage of the fluorogenic substrate Ac-DEVD-AMC. Data are means+/2SD from n=3 separate experiments. # p,0.05 difference from
control cells (Ctrl).
doi:10.1371/journal.pone.0002844.g001
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D, E). Furthermore, a DR5 blocking peptide (DR5 BP) also
abolished the synergistic effect between Tunicamycin and TRAIL
(Fig. 6 F), demonstrating that signalling through DR5 and,
downstream from this through Bid, was required for this
synergistic effect.
Bid deficiency protects against Etoposide-, Doxorubicin-
and Oxaliplatin induced apoptosis
To assess the potential contribution of Bid to DNA damage-
induced apoptosis in HeLa cells, we treated HeLa Bid kd cells and
HeLa control cells with the anticancer drugs Etoposide (Eto),
Oxaliplatin (Ox), and Doxorubicin. Detection of effector caspase
Figure 2. Bid depletion abrogates the death receptor-mediated apoptotic pathway. Control and HeLa Bid kd were pre-incubated with the
pan-caspase inhibitor zVAD-fmk (100 mM) for 1 h followed by treatment for the specified times with CHX (1 mg/ml) in combination with an agonistic
Fas antibody or recombinant TRAIL at the indicated concentrations. Controls were treated with vehicle. A, B) Caspase-3 like activity was measured by
cleavage of the fluorogenic substrate Ac-DEVD-AMC. Data are means+/2SD from n=3 separate experiments. # p,0.05 difference from control cells
(Ctrl). C, D) Cells were treated as indicated and lysates were subjected to Western blotting with a polyclonal caspase-3, a monoclonal Poly-ADP-Ribose
Polymerase (PARP) antibody and a monoclonal a-tubulin antibody. E, F) Cells were treated as indicated and apoptosis was assessed by flow
cytometric evaluation of Annexin-V FITC conjugated binding to phosphatidylserine in non-permeabilized cells. Data are means+/2SD from n=3
separate experiments. # p,0.05 difference from control cells (Ctrl).
doi:10.1371/journal.pone.0002844.g002
Bid in Apoptosis
PLoS ONE | www.plosone.org 4 July 2008 | Volume 3 | Issue 7 | e2844activation by activity assays indicated that the knockdown of bid
was able to confer a partial resistance to genotoxic drugs (Fig. 7 A–
C). A more detailed analysis was performed with the anti-cancer
drug oxaliplatin. Western blotting, flow cytometry analysis of
Annexin-V binding (Fig. 7 D, E) and clonogenic survival assays
(Fig. 8 A, B) indicated that the knockdown of bid conferred a
partial resistance to oxaliplatin. These protective effects of the bid
knockdown were confirmed by treatment of HeLa cells with the
Bid inhibitor BI6C9 (Fig. 9 A, B).
We next investigated the role of Bid in the potential synergism
between genotoxic drugs and TRAIL. Oxaliplatin and Etoposide
both upregulated DR5 receptor expression in a time-dependent
manner, while DR4 levels remained constant (Fig. 10 A, B).
Similar to our data obtained with ER stressors, we observed potent
synergistic effects of Oxaliplatin and Etoposide with TRAIL which
was completely abolished in Bid-deficient cells (Fig. 10 C, D).
Additive effects of Bid and PUMA in mediating
Oxaliplatin-induced apoptosis
Since the BH3-only gene puma has been shown to be a pivotal
regulator of apoptosis induced by DNA-damaging anticancer drugs
in many types of cancer cells and in particular to mediate
Oxaliplatin-induced apoptosis [42], we finally determined the
relative contributions of Bid and PUMA in apoptosis induced by
oxaliplatin. We compared the effects of Oxaliplatin on puma gene
expression in HeLa control cells and HeLa Bid kd cells. puma
mRNA levels were potently induced by Oxaliplatin as evaluated by
qPCR (Fig. 11 A). We could not observe significant differences in
puma mRNA upregulation between HeLa control and HeLa Bid kd
cells (Fig. 11 A), indicating that the stress signaling pathways
mediating puma expression were similarly activated in control and
Bid kd cells, and that the induction of puma occurred independently
of Bid. Transient RNA interference against puma was able to reduce
puma mRNA expression by 47.58+/28.7% and 64.61+/23.2%
after 24 h and by 59.71+/21.1% and 69.67+/20.1% after 48 h in
the HeLa control and HeLa Bid kd cells, respectively (n=3
experiments; normalized to b-actin mRNA expression and com-
pared to cultures transfected with a scrambled siRNA sequence).
Treatment withpumasiRNAsignificantlyreducedlevelsofapoptosis
in HeLa control cells exposed to Oxaliplatin (Fig. 11 B). The
knockdown of puma led to a further decrease of apoptosis in the
HeLaBidkdcells,indicatingthatbothBH3-onlyproteinscooperate
in mediating apoptosis triggered by Oxaliplatin.
Figure 3. Inhibition of death receptor-induced apoptosis correlates with enhanced clonogenic survival in HeLa Bid kd cells. Control
cells and HeLa Bid kd cells were treated with CHX (1 mg/ml) in combination with an agonistic FAS antibody or recombinant TRAIL for the indicated
times. Controls were treated with vehicle. After incubation, 1000 cells were transferred to 60 mm dishes and cultured with fresh medium for 14 days.
Then colonies were fixed, stained with methylene blue and counted. A, B) Colony formation in representative dishes is shown. C, D) Graphical
representation of the percentage of colonies after treatment compared to control cells treated with vehicle (100%). Data are means+/2SD from at
least two independent experiments performed in triplicate. # p,0.05: difference from control cells (Ctrl). p,0.05: difference from Bid kd cells
treated with vehicle.
doi:10.1371/journal.pone.0002844.g003
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Truncated Bid (t-Bid) can be generated by the activity of
caspase-8 and -10 [15,43] and has been described to be a very
potent BH3-only protein [6–8,9–11,44–46]. Furthermore, Bid is
constitutively expressed in many tumours and is cleaved by several
stress-activated proteases other than caspase-8 or -10 [21,23–29].
Given these special characteristics of Bid compared to other BH3-
only proteins, we established a stable knockdown of Bid expression
by a gene silencing approach in HeLa cervical carcinoma cells and
addressed the functional importance of Bid expression in death
receptor- and stress-induced apoptosis in a human cancer cell line.
In line with the well established role of Bid in linking the extrinsic
and intrinsic pathways of apoptosis, depletion of Bid by stable
RNA interference lead to a pronounced cellular resistance to Fas/
CD95- and TRAIL-mediated caspase activation and apoptosis. In
further experiments, we could confirm this finding using the
synthetic, cell-permeable Bid inhibitor BI6C9. Finally, silencing of
Bid also significantly increased the clonogenic survival of HeLa
cells treated with either the Fas/CD95 activating antibody or
recombinant TRAIL. These results indicate that in HeLa cervical
cancer cells, apoptosis signaling through Fas/CD95 and TRAIL
occurs almost exclusively in a Bid dependent manner, with the
direct activation of caspase 3 by caspase-8 insufficient to
compensate for a loss of Bid expression and to induce cell death.
Importantly, these results also suggest that in HeLa cervical cancer
Figure 4. Bid is dispensable for apoptosis triggered by the kinase inhibitor Staurosporine. Control and HeLa Bid kd cells were pre-
incubated with the pan-caspase inhibitor zVAD-fmk (100 mM) for 1 h before treatment with the indicated concentrations of Staurosporine for the
indicated times. A) Caspase-3 like activity was measured by cleavage of the fluorogenic substrate Ac-DEVD-AMC. Data are means+/2SD from n=3
separate experiments. n.s.=not significant versus control (Ctrl). B) Cells were treated as indicated and lysates were subjected to Western blotting with
a polyclonal caspase-3, a monoclonal Poly-ADP-Ribose Polymerase (PARP) antibody and a monoclonal a-tubulin antibody. C, D) The small molecule
Bid inhibitor BI6C9 mimics the effects of the knockdown of Bid in HeLa cells. Parental HeLa cells were pre-incubated with the indicated
concentrations of BI6C9 for 16 h prior to treatment with an agonistic Fas antibody, Staurosporine (STS) or vehicle, for 6 h. Apoptosis was assessed by
flow cytometric evaluation of Annexin-V FITC conjugated binding to phosphatidylserine in non-permeabilized cells. Data are means+/2SD from n=3
separate experiments. p,0.05: difference from control cultures treated with Fas antibody or Staurosporine in the absence of BI6C9.
doi:10.1371/journal.pone.0002844.g004
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[47] appear to play only a minor role in response to Fas/CD95
activation or TRAIL.
Activation of caspase-8 has also been suggested to play a
significant role during ER stress-induced apoptosis [34,48,49]. To
test the hypothesis that the caspase-8/Bid pathway is also a central
mediator of ER stress-induced cell death in human cancer cells, we
treated HeLa control cells and HeLa Bid kd cells with apoptosis-
inducing concentrations of three ER stressors, each having a
different mechanism of action (Tunicamycin, Thapsigargin, and
Figure 5. Bid is dispensable for endoplasmic reticulum (ER) stress-induced apoptosis. Control cells and HeLa Bid kd cells were pre-
incubated with the pan-caspase inhibitor zVAD-fmk (100 mM) where specified for 1 h before treatment with the ER stressors Tunicamycin, Brefeldin A,
and Thapsigargin at the indicated concentrations for the indicated times. A) Cell lysates were subjected to Western blotting with a monoclonal KDEL
antibody, which detects Grp94 and Grp78, and a monoclonal a-tubulin antibody. B, C, D) Caspase-3 like activity was measured by cleavage of the
fluorigenic substrate Ac-DEVD-AMC. Data are means+/2SD from n=3 separate experiments. n.s.=not significant versus control (Ctrl). E) Cells were
treated as indicated and lysates were subjected to Western blotting with a polyclonal caspase-3 antibody, a monoclonal Poly-ADP-Ribose Polymerase
(PARP) antibody and a monoclonal a-tubulin antibody. F) Apoptosis was assessed by flow cytometric evaluation of Annexin-V FITC conjugated
binding to phosphatidylserine in non-permeabilized cells. Data are means+/2SD from n=3 separate experiments. n.s.=not significant versus control
(Ctrl).
doi:10.1371/journal.pone.0002844.g005
Bid in Apoptosis
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(Fig. 6) or by treatment with BI6C9 (authors’ unpublished data)
did not reduce caspase activation and cell death induced by these
three ER stress stimuli. Our findings therefore support the data
from a previous study of Borner and co-workers [50] where Bid
expression was not required for ER stress mediated cell death.
Figure 7. Bid participates in apoptosis induced by genotoxic drugs. HeLa control and HeLa Bid kd cells were treated with the indicated
concentrations of Etoposide, Oxaliplatin and Doxorubicin, or vehicle, for 24 h; cells were pre-incubated with the pan-caspase inhibitor zVAD-fmk
(100 mM) for 1 h where specified. A, B, C) Caspase-3 like activity was measured by cleavage of the fluorogenic substrate Ac-DEVD-AMC. Data are
means+/2SD from n=3 separate experiments. # p,0.05 difference from control cells (Ctrl). D) Cells were treated as indicated and lysates were
subjected to Western blotting with a polyclonal Bid, a polyclonal caspase-3, a polyclonal Poly-ADP-Ribose Polymerase (PARP) antibody and a
monoclonal a-tubulin antibody. E) Apoptosis was assessed by flow cytometric evaluation of Annexin-V FITC conjugated binding to
phosphatidylserine in non-permeabilized cells. Data are means+/2SD from n=3 separate experiments. # p,0.05 difference from control cells (Ctrl).
doi:10.1371/journal.pone.0002844.g007
Figure 6. The synergistic effects of ER Stress and TRAIL on apoptosis depend on Bid. A) HeLa Control and HeLa Bid kd cells were pre-
incubated with the pan-caspase inhibitor zVAD-fmk for 1 h where specified; cells were subsequently treated with Tunicamycin or vehicle for the
indicated times. Cell lysates were subjected to Western blotting with a polyclonal DR4, a polyclonal DR5, and a monoclonal b-actin antibody. B, C)
Control cells and HeLa Bid kd cells were pre-incubated for 16 h with the indicated concentrations of Tunicamycin, Thapsigargin or vehicle before
treatment with TRAIL (10 ng/ml). Caspase-3 like activity was measured by cleavage of the fluorogenic substrate Ac-DEVD-AMC. Data are means+/
2SD from n=3 separate experiments. p,0.05: difference from Tunicamycin, Thapsigargin or TRAIL individual treatments. # p,0.05: difference
from control cells (Ctrl). D) Control cells and HeLa Bid kd cells were pre-incubated with Tunicamycin (0.3 mM) or vehicle for the indicated times
followed by treatment with TRAIL (10 ng/ml) for the indicated times. Cell lysates were subjected to Western blotting with a polyclonal Bid, a
polyclonal caspase-3, a polyclonal Poly-ADP-Ribose Polymerase (PARP) antibody and a monoclonal a-tubulin antibody. E) Control cells and HeLa Bid
kd cells were pre-incubated with Tunicamycin (0.3 mM) for 16 h followed by treatment with recombinant TRAIL (10 ng/ml) for the indicated times.
Apoptosis was assessed by flow cytometric evaluation of Annexin-V FITC conjugated binding to phosphatidylserine in non-permeabilized cells. Data
are means+/2SD from n=3 separate experiments. p,0.05: difference from Tunicamycin or TRAIL individual treatments. # p,0.05: difference from
control cells (Ctrl). F) Control cells and HeLa Bid kd cells were pre-incubated with a DR5 blocking peptide (50 ng/ml) for 1 h followed by pre-
treatment with Tunicamycin (0.3 mM) or vehicle for 16 h. Subsequently, cells were treated with recombinant TRAIL for 3 h. Caspase-3 like activity was
measured by cleavage of the fluorogenic substrate Ac-DEVD-AMC. Data are means+/2SD from n=3 separate experiments. p,0.05: difference
from Tunicamycin or TRAIL individual treatments. # p,0.05: difference from control cells (Ctrl).
doi:10.1371/journal.pone.0002844.g006
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subtoxic concentrations of the ER stressors Tunicamycin or
Thapsigargin were combined with subtoxic concentrations of
TRAIL. Indeed, the synergistic effect of Tunicamycin and TRAIL
was completely abolished by the Bid knockdown. In subsequent
experiments, we were able to show that ER stress induced by
Tunicamycin or Thapsigargin was associated with enhanced
expression of the death receptor DR5 as reported previously by
our and other groups [51–53], while we did not detect any
expression changes of the death receptor DR4. The synergistic
effects of TRAIL and Tunicamycin could be completely blocked
with a specific DR5 blocking peptide demonstrating that signaling
through DR5 was required for this synergism [52,53]. However,
the relevance of upregulated DR5 expression for enhanced
TRAIL DISC formation and stress-triggered sensitization of
cancer cells to TRAIL-induced apoptosis is controversially
discussed [41,54,55], as it may also result from an enhanced
binding of caspase-8 to the DISC. Nevertheless, our data indicate
that in either scenario, signaling through Bid is absolutely required
for the synergism of ER stressors and TRAIL.
Despite the considerable interest in TRAIL or agonistic
TRAIL-receptor antibodies as anticancer agents, accumulating
evidence suggests that indeed mono-therapies with these agents
may have limited success, but that synergistic treatments with
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Figure 8. Knockdown of Bid improves clonogenic survival after treatment with Oxaliplatin. HeLa Control and HeLa Bid kd cells were
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Figure 9. The synthetic Bid inhibitor BI6C9 protects HeLa cells from apoptosis induced by genotoxic drugs. A, B) Parental HeLa cells
were pre-incubated with the indicated concentrations of BI6C9 or the pan-caspase inhibitor z-VAD (100 mM) for 16 h, prior to treatment with 15 mg/
ml (A) or 30 mg/ml (B) Oxaliplatin or vehicle for 24 h. Apoptosis was assessed by flow cytometric evaluation of Annexin-V FITC conjugated binding to
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treated with Oxaliplatin in the absence of BI6C9.
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activate apoptosis in many types of cancers [53,56–59]. Indeed a
similar synergism, described previously in other tumor cells [60–
63], and its strict dependence on Bid expression were observed
when TRAIL was combined with the genotoxic drugs, Oxaliplatin
or Etoposide. It is well established that many anti-cancer drugs
including Oxaliplatin and Etoposide induce the tumor suppressor
p53 which is able to transcriptionally activate DR5 expression but
also bid expression [13,64]. These endogenous cell death ‘back up’
mechanisms, in co-operation with an enhanced ability to recruit
caspase-8 to the DISC, therefore provide a biological framework
that can be therapeutically explored by these combined treatment
paradigms. Interestingly, in our previous trancriptome profiling of
cells undergoing ER stress mediated apoptosis [51] we noted a
distinct lack of p53 target genes, suggesting that the upregulation
of DR5 by ER stressors may occur independent of p53 expression.
Therefore, in tumours where the p53 signaling pathway is lost/
mutated the TRAIL agonists in combination with ER stressors
may be of better therapeutic benefit than their utilization in
combination with genotoxic drugs.
In cancer cells treated with genotoxic drugs only, the p53 target
gene puma has been suggested to largely mediate the pro-apoptotic
activity of p53 [65–67]. In our study, puma was potently activated
by Oxaliplatin in HeLa control and Bid kd cells, and transient
RNA interference against puma was able to significantly reduce
apoptosis in both cell lines. Despite the prominent role of PUMA
in mediating genototoxic drug-induced apoptosis, several lines of
evidence support the notion that Bid also partially contributes to
apoptosis induced by DNA-damage [68–71]. In contrast to its
death-inducing role in apoptosis, Bid has also been implicated in
protecting cells from genotoxic stress by promoting cell cycle arrest,
thus facilitating DNA repair and potentially cellular survival
[70,72]. Our Bid-deficient cells displayed significantly reduced
levels of caspase activation in response to the DNA-damaging anti-
cancer drugs Etoposide, Oxaliplatin and Doxorubicin. Follow-on
experiments with Oxaliplatin demonstrated reduced cell death as
well as an increased clonogenic survival in the Bid-deficient cells,
but this effect was less dramatic than that observed after treatment
with the death ligands TRAIL or Fas. Apart from the involvement
of alternative BH3 only proteins, in particular PUMA in
Oxaliplatin-induced apoptosis, the proposed dual function of Bid
in apoptosis and preservation of genomic integrity may also
explain the less pronounced effect of the Bid knockdown on cell
death and clonogenic survival in response to Oxaliplatin. Our
results differ from a previous report in which the effect of bid gene
deletion was explored in non-transformed murine cells [37]. In
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proposed protective function. The integration of BH3 only
proteins into stress-induced signalling pathways may have also
evolved differently between murine and human cells [73,74].
A further level of complexity in regard to the role of Bid in the
response to genotoxic stress lies in the fact that Bid can be
activated through several distinct mechanisms after DNA damage.
In addition to its transcriptional induction, Bid has been shown to
be proteolytically activated by the initiator caspase, caspase-2, and
generation of t-Bid has been suggested to be essential for apoptosis
induced by caspase-2 [21]. Activation of calpains has also been
implicated in this context [75]. Furthermore, in some scenarios,
full length Bid is also able to translocate to mitochondria and
trigger the intrinsic pathway of apoptosis without previous
proteolytic activation [14,30–32,77–78]. Bid therefore appears to
be a target of several signaling pathways that co-operate with the
induction of other BH3 Only Proteins such as PUMA in mediating
genotoxic drug-induced apoptosis.
Collectively, our data demonstrate that Bid is an indispensable
component of death receptor-induced cell death, but also
participates in DNA damage-induced apoptosis of human cervical
cancer HeLa cells. Importantly, our data also show that the
synergistic effects of the death ligand TRAIL in combination with
either ER stressors or DNA damaging anti-cancer drugs are nearly
exclusively mediated via an increased activation of Bid-induced
apoptosis signaling.
Materials and Methods
Materials
Human recombinant TRAIL was purchased from Leinco
Technologies (Universal Biologicals, Gloucestershire, UK). Cas-
pase substrate N-acteyl-Asp-Glu-Val-Asp-7-amino-4-methyl-cou-
marin (Ac-DEVD-AMC) and the pan-caspase inhibitor Z-Val-
Ala-Asp(O-methyl)-fluoromethylketone (zVAD-fmk) were ob-
tained from Bachem (St. Helen’s, UK). All other chemicals came
in analytical grade purity from Alexis (Blessington, Ireland) or
Sigma-Aldrich (Dublin, Ireland).
Cell culture
HeLa cells were grown in RPMI 1640 medium supplemented
with 10% (v/v) heat-inactivated fetal calf serum, 2 mM glutamine,
100 U/ml penicillin, and 100 mg/ml streptomycin (Sigma-Aldrich)
ina humidified 5%CO2 containingatmosphere at 37uC.Cells were
kept in logarithmic growth phase by routinely passaging them twice
a week and were plated 24 h prior to treatments.
Generation of stable bid knockdown and control clones
The following shRNA sequences specific for human Bid mRNA
weredesignedusingthe Dharmacon siRNA designtool(http://www.
dharmacon.com/sidesign/): Bid-1 sense (59-AAGCTGTTCTGA-
CAACAGC-39), Bid-2 sense (59-AAGGAGAAGACCATGCTGG-
39)a n dB i d - 3s e n s e( 5 9-AAGAATAGAGGCAGATTCT-39). Bid-
specific or control shRNA duplexes were ligated into the pSilencer 2.1-
U6 hygro vector (Ambion, Cambridgeshire, UK) via their BamHI
and Hind III sites. To generate stableknockdown cell lines HeLa cells
were transfected with the different shRNA constructs using
Metafectene (Biontex, Munich, Germany) according to the manu-
facturer’s instructions. 24 h post transfection the cells were (serially)
diluted, transferred to 96-well plates and stable clones were selected
using hygromycin B (160 mg/ml).
Stable clones expressing ectopically re-introduced Bid were
generated as outlined above by using a pFRET-Bid plasmid (kind
gift from Dr. R. Onuki, National Institute of Advanced Industrial
Science and Technology, Tsukuba, Japan) [79], expressing a YFP-
Bid-CFP fusion protein.
Transient RNA interference
siRNA duplexes targeting puma mRNA were designed utilizing
the RNA workbench (www.rnaworkbench.com). The annealed
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control siRNA (59-UUCUCCGAACGUGUCACGUdTdT-39)
duplexes were purchased from Sigma Proligo (Paris, France).
24 h after seeding into six-well plates, cells were transfected with
100 nM of the siRNA duplex using Metafectene Pro (Biontex,
Munich, Germany) as per manufacturer’s instructions. 24 h post
transfection cells were treated as indicated.
SDS-PAGE and Western blotting
Preparation of cell lysates and western blotting was performed
as previously described [80]. The following primary antibodies
were used: a rabbit polyclonal APAF-1 (Chemicon, Carrigtwohill,
Ireland), a rabbit polyclonal Bad or caspase-3 (Cell Signaling,
Bray, Ireland), a mouse monoclonal Bak or Bcl-2 (Santa Cruz,
Heidelberg, Germany), a rabbit polyclonal Bax (Upstate, Carrigt-
wohill, Ireland), a rabbit polyclonal Bcl-X (BD Biosciences,
Erembodgem, Belgium), a mouse monoclonal Bim or caspase-8
(Alexis Biochemicals, Blessington, Ireland), a goat polyclonal Bid
(R&D Systems, Abingdon, UK), a rabbit polyclonal caspase-9
(Calbiochem, Darmstadt, Germany), a rabbit polyclonal DR4 or
DR5 (Abcam, Cambridge, UK), a rabbit poyclonal GFP
(Clontech, Oxford, UK), a mouse monoclonal KDEL (Stressgen,
York, UK), a rabbit polyclonal cleaved PARP (NEB, Bray,
Ireland), a rabbit polyclonal smac/DIABLO (R&D Systems), a
mouse monoclonal XIAP (BD Biosciences), a mouse monoclonal
b-actin or a-tubulin (Sigma Aldrich, Dublin, Ireland). Horseradish
peroxidase-conjugated secondary antibodies (Jackson Immuno
Research, Cambridge, UK) were detected using SuperSignal West
Pico Chemiluminescent Substrate (Pierce) and imaged using a
FujiFilm LAS-3000 imaging system (Fuji).
Flow cytometry
The measurement Annexin-V-FITC-staining of apoptotic cells
was performed on a Cyflow ML16 flow cytometer (Partec,
Mu ¨nster, Germany) as described previously [81].
Real-time qPCR
Total RNA was extracted using the RNeasy Mini kit (Qiagen,
Hilden,Germany) and 2 mg per sample were reverse-transcribed into
first strand cDNA using random hexamer primers (50 pmol) and
MMLV Reverse Transcriptase (Invitrogen, Dun Laoghaire, Ireland).
Quantitative real-time PCR was conducted using the QuantiTech
SYBR Green PCR kit (Qiagen) and the LightCycler (Roche
Diagnostics, Lewes, UK) as described previously [81]. Primers were
designed using Primer3 software (http://frodo.wi.mit.edu/cgi-bin/
primer3/primer3_www.cgi) and came from Sigma-Genosys (Cam-
bidge, UK). Sense and antisense primers were: b-actin: TCACCCA-
CACTGTGCCCATCTA and CAGCGGAACCGCTCATTGC-
CAA; puma: CCATCTCAGGAAAGGCTGTT and ACGTT-
TGGCTCATTTGCTCT.
Determination of caspase-3-like protease activity
Preparation of cell lysates to determine their caspase-3-like
protease-activity was performed as previously described [80].
Cleavage of the fluorigenic substrate DEVD-AMC was monitored
by measuring the accumulation of fluorescent AMC after 1 and 2 h
using a GENios microplate reader (Tecan, Crailsheim, Germany).
Protein content was determined using the Coomassie Plus Protein
assay reagent (Pierce, Dublin, Ireland). Caspase activity was
expressed as change in fluorescence per mg of protein and hour.
Colony formation assay
Cells were treated as indicated before transferring 1,000 cells to
60 mm dishes and culturing them for two weeks to allow for
colony formation. Then the medium was removed, colonies were
fixed and stained with a solution containing ethanol (50%) and
methylene-blue (0.25%) (Sigma-Aldrich, Dublin, Ireland) for
45 min and the number of colonies per plate was counted.
Statistics
Data are given as means6SD or SEM. For statistical
comparison, t-test or one-way ANOVA followed by Tukey test
were employed using SPSS software (SPSS GmbH Software,
Munich, Germany). P-values smaller than 0.05 were considered to
be statistically significant.
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